[go: up one dir, main page]

WO1999057241A2 - Peptides de proteine basique de myeline et utilisations de ceux-ci - Google Patents

Peptides de proteine basique de myeline et utilisations de ceux-ci Download PDF

Info

Publication number
WO1999057241A2
WO1999057241A2 PCT/US1999/009930 US9909930W WO9957241A2 WO 1999057241 A2 WO1999057241 A2 WO 1999057241A2 US 9909930 W US9909930 W US 9909930W WO 9957241 A2 WO9957241 A2 WO 9957241A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
mbp
amino acid
class
myelin basic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/009930
Other languages
English (en)
Other versions
WO1999057241A9 (fr
WO1999057241A3 (fr
Inventor
Subhashini Arimilli
Shrikant Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99920379A priority Critical patent/EP1080185A4/fr
Priority to NZ507901A priority patent/NZ507901A/xx
Priority to HK02101092.3A priority patent/HK1039636A1/zh
Priority to AU37890/99A priority patent/AU3789099A/en
Priority to CA002330826A priority patent/CA2330826A1/fr
Priority to JP2000547197A priority patent/JP2002513558A/ja
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO1999057241A2 publication Critical patent/WO1999057241A2/fr
Publication of WO1999057241A3 publication Critical patent/WO1999057241A3/fr
Publication of WO1999057241A9 publication Critical patent/WO1999057241A9/fr
Priority to NO20005547A priority patent/NO20005547L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the binding of a peptide to a peptide binding site is dependent on the primary amino acid sequence of both the peptide and the Class II molecule. Only high affinity binding between a peptide and a Class II polypeptide will form a complex which will be presented extracellularly to T cells. The affinity, or strength, of this intermolecular attraction is determined by the same factors that exist for all peptide:polypeptide binding reactions, e.g., conformation, hydrogen bonding, charge, ionic interactions.
  • the limitations created by primary sequence are further limited by a size limitation; the peptide binding site is believed to be able to accomodate peptides ranging from about eight to about twenty amino acids in length (the "agretope” is that portion of the peptide recognized by the MHC molecule).
  • the “agretope” is that portion of the peptide recognized by the MHC molecule.
  • different portions of an antigenic polypeptide are typically presented by different Class II molecules.
  • a peptide is internalized by an APC and proteolytically processed into fragments, only a single or small number of peptides will bind with high affinity, i.e., be "specifically bound," to a specific Class II molecule.
  • Class II molecules As only a limited number of Class II molecules are expressed in an individual, only a limited repetoire of peptides from a polypeptide antigen are presented.
  • MBP 83-102 MBP peptide spanning residues 83 to 102
  • TCR T cell's clonally specific receptor
  • T cell inducing its clonal proliferation and secretion of immunomodulatory cytokines (which can be stimulatory or immunosuppressive).
  • immunomodulatory cytokines which can be stimulatory or immunosuppressive.
  • the response can be an autoimmune reaction.
  • Interfering with the ability of peptide:Class II complex binding to TCR can inhibit the development of or suppress an autoimmune reaction.
  • administration of antibodies to MHC Class II polypeptides can interfere with complex:TCR binding and the resultant pathogenic immune reaction.
  • Antibodies to autoreactive TCR or T cell clones can have the same effect.
  • An alternative immunosuppressive strategy can be used to exploit the need for a co-stimulatory signal to the T cell by the APC.
  • TCR binding by CD4+ T cells TCR binding by CD4+ T cells
  • Class ILpeptide is not sufficient.
  • An additional, "co-stimulatory" signal is needed (not an MHC molecule).
  • the required co-stimulatory signal is provided by an APC cell surface protein.
  • interaction of Class ILpeptide with TCR without APC co-stimulation not only does not induce T cell activation, but it also results in a state of antigen-specific unresponsiveness on rechallenge, known as anergy in vitro and tolerance in vivo (Boussiotis (1994) Curr. Opin. Immunol. 6:797-807; Park (1997) Eur. J. Immunol. 27: 1082- 1090).
  • MBP 83-102 may be the immunodominant, naturally processed MBP peptide in some individuals, synthetic or recombinant modifications of myelin or peptide MBP 83-102 which bind to Class II molecule and/or T cell receptor with greater affinity can be therapeutically efficacious.
  • Such peptides would be better reagents to inhibit the pathogenic autoimmune reaction, e.g., through their administration as tolerance- inducing soluble Class ILpeptide complexes.
  • the present invention fulfills these and other needs.
  • the invention provides an isolated myelin basic protein (MBP) peptide, said peptide characterized by having an amino acid sequence Phe -X - Lys - Asn - He - Val - X - X - X - Thr - X -X, wherein X is any amino acid.
  • MBP myelin basic protein
  • the isolated myelin basic protein peptide is characterized by having an amino acid sequence Phe - Phe - Lys - Asn
  • the isolated myelin basic protein peptide can be linked to a heterologous sequence. In one embodiment, linkage of the myelin basic protein peptide to a heterologous sequence results in a fusion protein.
  • the invention also provides an isolated myelin basic protein peptide which specifically binds to an antibody directed against a peptide characterized by having an amino acid sequence Phe - Phe - Lys - Asn - He - Val - Thr - Pro - Arg - - Pro - Pro.
  • the invention provides an isolated nucleic acid encoding a myelin basic protein peptide, said peptide characterized by having an amino acid sequence Phe - X - Lys - Asn - He - Val - X - X - X - Thr - X - X , wherein X is any amino acid.
  • the encoded myelin basic protein peptide can be characterized by having an amino acid sequence Phe - Phe -. Lys - Asn - He - Val - Thr - Pro - Arg - Thr - Pro - Pro , or a conservative substitution thereof.
  • the isolated nucleic acid comprises SEQ ID NO:l .
  • the invention also provides a composition comprising an MHC Class II complex capable of binding a T cell receptor, the complex consisting essentially of: an MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket, said component being encoded by an allele associated with an autoimmune disease directed to myelin basic protein, wherein the Class II component is soluble under physiological conditions in the absence of detergent or lipid; and, a myelin basic protein having an amino acid sequence Phe -X - Lys - R, - He - Val - X - X - X - Thr - X -X , wherein X is any amino acid, and R, is Asn or Gin; wherein the myelin basic protein peptide is bound to the MHC Class II component antigen binding pocket.
  • the myelin basic protein peptide can have an amino acid sequence Phe - Phe - Lys - Asn - He - Val - Thr - Pro - Arg - Thr - Pro - Pro, or a conservative substitution thereof.
  • the composition can comprise a fusion protein and/or an effector composition.
  • the autoimmune disease is multiple sclerosis, or the class II polypeptide comprises the antigen binding pocket of an HLA DR2.
  • X is any amino acid.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a composition comprising an MHC class II complex capable of binding a T cell receptor, the complex consisting essentially of: an MHC class II polypeptide comprising an extracellular domain of an MHC class II molecule sufficient to form an antigen binding pocket, said component being encoded by an allele associated with an autoimmune disease directed to myelin basic protein, wherein the class II component is soluble under physiological conditions in the absence of detergent or lipid; and, a myelin basic protein having an amino acid sequence Phe -X - Lys - R, - He - Val - X - X - X - Thr - X -X , wherein X is any amino acid, and R, is
  • the invention provides an antibody, specifically immunoreactive under immunologically reactive conditions, to a myelin basic protein peptide, said peptide characterized by having an amino acid sequence Phe - Phe - Lys - Asn - He - Val - Thr - Pro - Arg - Thr - Pro - Pro.
  • the invention provides an antibody is specifically immunoreactive under immunologically reactive conditions, to a myelin basic protein peptide comprising the peptide encoded by a nucleic acid of encoding a myelin basic protein peptide, said peptide characterized by having an amino acid sequence Phe - X - Lys - Asn - He - Val - X - X - X - Thr - X - X , wherein X is any amino acid.
  • the invention provides a method for inhibiting a T cell mediated immune response against myelin basic protein in a subject, comprising administering to the subject an isolated myelin basic protein (MBP) peptide, said peptide characterized by having an amino acid sequence Phe -X - Lys - Asn - He - Val - X - X - X - Thr - X -X, wherein X is any amino acid, in an amount effective to treat the T cell mediated immune response.
  • MBP myelin basic protein
  • the invention provides a method for inhibiting a T cell mediated immune response against myelin basic protein in a subject, comprising administering to the subject a composition comprising an MHC Class II complex capable of binding a T cell receptor, the complex consisting essentially of: an MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket, said component being encoded by an allele associated with an autoimmune disease directed to myelin basic protein, wherein the Class II component is soluble under physiological conditions in the absence of detergent or lipid; and, a myelin basic protein having an amino acid sequence Phe -X - Lys - R, - He - Val - X - X - X - Thr - X -X , wherein X is any amino acid, and R, is Asn or Gin; wherein the myelin basic protein peptide is bound to the MHC
  • the invention provides a method for inhibiting a T cell mediated immune response against myelin basic protein in a subject wherein the T cell mediated immune response causes a pathology to a neurological system.
  • the pathology to the neurological system is characterized as multiple sclerosis.
  • the invention provides a method of identifying a T cell epitope on an antigen which, when bound to the antigen binding pocket of an MHC Class II molecule, is capable of binding to a T cell receptor, such binding triggering an extracellular acidification reaction by a T cell expressing the T cell receptor, said method comprising the steps of: a) providing a composition comprising the T cell epitope bound to the antigen binding pocket of an MHC
  • Figure 1 A shows the MBP peptides used in the studies described in Example 1.
  • Figure IB shows MBP peptides with various alanine substituted residues used in the studies described in Example 1.
  • Figures 2A, 2B and 2C show the results of analyses described in Example 1, demonstrating increased levels of gamma-IFN, TNF-beta and extracellular acidification rates, respectively, with six N-terminal truncated MBP peptides.
  • Figures 2D, 2E and 2F show results of analyses described in Example 1, comparing the gamma-IFN, TNF-beta and acidification rates, respectively, of five N-terminus truncated MBP peptides.
  • Figures 3 A, 3B, and 3C show the results of analyses described in Example 1, comparing the gamma-IFN, TNF-beta and acidification rates, respectively, induced by
  • FIGS. 3D, 3E, and 3F show the results of analyses described in Example 1, comparing the gamma-IFN, TNF-beta and acidification rates, respectively, induced by C-terminal truncated MBP peptides.
  • Figures 4A, 4B and 4C show the results of analyses described in Example 1, demonstrating MBP peptide residues necessary to induce gamma-IFN, TNF-beta along with increased acidification rates, respectively, when presented to SS8T cells by Class II DRB5*0101.
  • Figures 4D, 4E and 4F show the results of analyses described in Example 1, demonstrating MBP peptide residues necessary to induce gamma-IFN, TNF-beta along with increased acidification rates, respectively, when presented to SS8T cells by Class II DRB5*0101.
  • Figure 5A shows, in highlights (boxed area), the core TCR recognition sequence as MBP(91-100) (SEQ ID NO:38).
  • Figure 5B shows (by arrows) the important MBP amino acid residues involved in TCR contact as F-91, K-93, N-94, 1-95, and V-96.
  • the present invention is directed to methods and compositions that can be used to inhibit those aspects of the immune system which are responsible for undesirable autoimmunity.
  • This invention is a first description of a novel set of peptides derived from human myelin basic protein (MBP) that can be used in the treatment of autoimmune mediated demyelinating disease, in particular, multiple sclerosis (MS).
  • MBP myelin basic protein
  • MS multiple sclerosis
  • the invention provides therapeutic compositions comprising novel MBP peptides for, e.g., inducing oral or general tolerance.
  • a soluble MBP peptide:Class II molecule complex for targeting T cells mediating the autoimmune reaction.
  • the complex targets T cell clones reactive to MBP by binding to autoreactive T cell receptor (TCR) capable of binding the MBP:Class II complex.
  • TCR autoreactive T cell receptor
  • compositions of the invention are pharmaceutically active by, e.g., inducing T cell clonal anergy and tolerance or inducing a cytokine-mediated immunosuppressive immune response.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a peptide characterized by having an amino acid sequence Phe -X - Lys - Asn - He - Val - X - X - X - Thr - X -X, wherein X is any amino acid.
  • Administration of the peptide alone can be used to induce oral tolerance, which is a phenomenon of systemic, antigen specific, immunological hyporesponsiveness that results from oral administration of a protein. The mechanism by which oral tolerance is generated depends on the amount of antigen (peptide) administered. Low doses favor induction of regulatory immunosuppressive helper CD4+ T cells.
  • Orally administered autoantigens have been shown to suppress a wide variety of experimental autoimmune diseases, including the most widely studied animal model for MS, the murine demyelinating disease experimental autoimmune encephalomyelitis (EAE).
  • Murine MBP peptide has been used to generate an antigen-specific oral tolerance and to prevent development of acute EAE (Bitar (1988) Cell.
  • the present invention is also directed to purified complexes comprising at least an effective antigen-binding portion of a dimeric Class II molecule or a single chain (monomeric) subunit of a Class II and an MBP peptide of the invention.
  • An "effective antigen-binding portion" is the mininum amount of dimeric or monomeric Class II molecule necessary to bind MBP peptide with sufficient affinity to create a complex capable of being recognized by and specifically bind to an autoreactive TCR.
  • the complex of the invention comprising MBP peptide and the appropriate Class II molecule, can be bound or otherwise associated together covalently or noncovalently.
  • a third component, such as an "effector” component can also be included in the complex of the invention.
  • the effector component can be a cytotoxic agent, i.e., a toxin, radioisotope, apoptotic-inducing agent, and the like, to selectively eliminate or neutralize the targeted, autoimmune T cell population.
  • the invention is directed to pharmaceutical compositions wherein the peptide and complexes of the invention are the active ingredients. These compositions are used to down-regulate or eliminate autoreactive components of the immune system and to treat autoreactive, demyelinating, T cell mediated immune responses.
  • the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the MBP peptide:Class II complex.
  • the complexes selectively bind MBP autoreactive T cells. While the invention is not limited to any specific means by which the compositions can be pharmaceutically active, the peptides and complexes can induce clonal anergy/ tolerance or induce a cytokine-mediated immunosuppressive immune response.
  • the complexes can be further conjugated to cytotoxic agents to specifically eliminate targeted autoreactive T cells.
  • This invention provides novel myelin basic protein (MBP) peptides and complexes of these MBP peptides and MHC Class II polypeptides comprising at least the extracellular domain of a Class II molecule sufficient to form an antigen binding pocket, and nucleic acid encoding these MBP peptides and Class II polypeptides.
  • MBP myelin basic protein
  • the invention provides recombinantly generated nucleic acid, MBP peptides, and Class II polypeptides.
  • nucleic acid encoding these peptides and proteins can be expressed in vitro or in vivo
  • the invention provides for a variety of means of expressing these sequences, including expression cassettes, vectors, cell lines, transgenic plants and animals, and the like.
  • the MBP peptide- and MBP: Class II complex-encoding genes and nucleic acids of this invention can be isolated from a variety of sources; genetically engineered; expressed recombinantly; or synthesized in vitro.
  • Nucleic acids encoding for the MBP and MBP:Class II complexes of the invention can be expressed in transgenic plants and animals, transformed cells and cell lines, in a transformed cell lysate, or in a partially purified or a substantially pure form.
  • Nucleic acids and proteins are detected, isolated and quantified in accordance with the teachings and methods of the invention described herein by any of a number of general means well known to those of skill in the art. These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays
  • analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography
  • various immunological methods such as fluid or gel precipitin reactions, immunodiffusion
  • ELISAs immuno-fluorescent assays
  • Southern analysis Northern analysis
  • Dot-blot analysis gel electrophoresis
  • RT-PCR quantitative PCR
  • other nucleic acid or target or signal amplification methods radiolabeling, scintillation counting, and affinity chromatography.
  • Mutations can be introduced into a nucleic acid by a variety of conventional techniques, well described in the scientific and patent literature. For example, one rapid method to perform site-directed mutagenesis efficiently is the overlap extension polymerase chain reaction (OE-PCR) (Urban (1997) Nucleic Acids Res. 25:2227-2228). MHC Class II DR Alleles
  • the invention provides nucleic acids encoding novel myelin basic protein (MBP) peptides and MHC Class II polypeptides comprising at least the extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket.
  • MBP myelin basic protein
  • the invention provides an example of human DR Class II alleles encoding polypeptide capable of binding the MBP peptides of the invention, specifically, the alleles designated DRB 1*1501 and DRB5*0101 (see, e.g., Weber (1993) Proc. Natl. Acad. Sci. 90:11049-11053).
  • the complexes of the invention are not limited to these DR alleles or their corresponding Class II polypeptides.
  • the MBP:Class II complexes of the invention include any polypeptide comprising an MHC Class II antigen binding pocket, or functional equivalent thereof, which can bind an MBP peptide of the invention with sufficient affinity to be used in the methods of the invention.
  • Means to identify known such DR alleles and Class II polypeptides are well known in the scientific and patent literature, e.g., through electronic databanks, as Medline,
  • GenBank and the like.
  • Means to identify MHC Class II DR alleles encoding polypeptide having an antigen binding pocket capable of binding a particular peptide, such as, e.g., an MBP peptide of the invention, are also well known in the scientific and patent literature (see, e.g., Rammensee (1995) Immunogenetics 41 : 178-228; Sinigaglia (1994) Curr. Opin. Immunol. 6:52-56).
  • the Class ILpeptide complexes are water soluble. Water solubility can be engineered in Class II polypeptides by deleting transmembrane domain (typically hydrophobic) amino acid residues.
  • transmembrane domain can be by outright deletion of residues or by recombinantly redesigning Class II coding sequence to substitute hydrophobic residues with hydrophilic residues. This also facilitates recovery of the water-soluble Class II polypeptide after recombinant expression.
  • the transmembrane-inactivated Class II can be secreted directly into the culture medium of recombinant expression hosts. Further deletion of cytoplasmic or extracellular residues can be effective in eliminating potentially immunogenic epitopes.
  • a nucleic acid is designed to recombinantly express a minimal peptide binding site/TCR binding polypeptide, i.e., only the amount of polypeptide needed to bind the MBP peptide of the invention with sufficient affinity to be recognized by the appropriate autoreactive TCR and to be used in the methods of the invention.
  • the peptide-binding polypeptide whether in the form of a minimal peptide binding site molecule, an isolated or recombinant full length, alterred or truncated Class II molecule, or the like, can be in dimeric or moneric form.
  • Additional Class II polymorphic DR alleles can be identified and characterized using various methods, including: i) computer searches of DNA databases for DNAs containing sequences conserved with the Class II DR molecules described above, ii) hybridization with a probe from a known DR gene sequence to mRNA, cDNA or DNA sequence or libraries, and, iii) by PCR or other signal or target amplification technologies using primers complementary to regions highly conserved among different DR genes.
  • Nucleic acid amplification methods can also used to identify, isolate and generate Class II polymorphic alleles. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Innis, Academic Press, Inc., N.Y. (Innis )); ligase chain reaction (LCR) (Wu (1989) Genomics 4:560; Landegren (1988) Science 241 :1077; Barringer (1990) Gene 89:117); transcription amplification (Kwoh (1989) Proc.
  • PCR PROTOCOLS A GUIDE TO METHODS AND APPLICATIONS
  • LCR ligase chain reaction
  • MBP- and Class II-encoding nucleic acid Sequencing of isolated MBP- and Class II- encoding nucleic acid is used, e.g., to identify and characterize allelic DR species encoding polypeptides capable of binding MBP peptides; to confirm sequences of synthetically manufactured or cloned nucleic acid; confirm mutations; and the like.
  • MBP- and Class Il-encoding sequences can be sequenced as inserts in vectors, as inserts released and isolated from the vectors or in any of a variety of other forms (i.e., as amplification products).
  • MBP- and Class Il-encoding inserts can be released from the vectors by restriction enzymes or amplified by PCR or transcribed by a polymerase.
  • primers based on the N- or C- terminus, or based on insertion points in the original phage or other vector can be used.
  • a variety of nucleic acid sequencing techniques are well known and described in the scientific and patent literature, see, e.g. Rosenthal (1987) supra; Arlinghaus (1997) Anal Chem. 69:3747-3753; Dubiley (1997) Nucleic Acids Res. 25:2259-2265; for use of biosensor chips for identification and sequencing of nucleic acids.
  • the invention provides methods and reagents for recombinant expression of the novel MBP peptides and Class II molecules used in the complexes of the invention.
  • the nucleic acids of the invention may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. See, e.g., Roberts (1987) Nature 328:731 ; Berger (1987) supra; Schneider (1995) Protein Expr. Purif 6435:10; Sambrook, Tijssen or Ausubel. Product information from manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods.
  • the promoters and vectors used in this invention can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods, as described herein. A few selected illustrative general and specific teaching examples relevant to such technology are described below.
  • the invention providing methods and reagents for making the novel nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational cis- (e.g., promoters and enhancers) and trans-acting control elements.
  • the expression of natural, recombinant or synthetic MBP peptide- or polypeptide-encoding nucleic acids can be achieved by operably linking the coding region a promoter (that can be tissue-specific, constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an in vitro reaction system or a suitable host cell or organism.
  • Transcriptional and translational control elements include transcription and translation initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA.
  • a promoter fragment can be employed to direct expression of the desired nucleic acid in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation.
  • the expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette in vivo, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems.
  • a polyadenylation region at the 3 '-end of the coding region can be included.
  • the nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, e.g., episomal expression systems. Expression vectors capable of expressing proteins are well known in the art.
  • Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required.
  • the marker may encode antibiotic resistance, particularly resistance to chloramphenicol, kanamycin,
  • the invention provides for a variety of in vivo systems expressing the MBP peptides, Class II polypeptides, and peptide:Class II complexes of the invention, including transformed cells and transgenic plants and animals.
  • In vivo expression systems that can be used include bacterial, yeast, insect (baculovirus), plant, and mammalian cell systems. The system used will depend on a variety of factors, including activities and amounts desired.
  • This invention provides novel myelin basic protein (MBP) peptides, Class II polypeptides comprising at least an amount of polypeptide needed to bind an MBP peptide of the invention with sufficient affinity to be recognized by the appropriate autoreactive TCR, and Class ILMBP peptide complexes.
  • MBP myelin basic protein
  • the invention provides isolated (from natural sources), synthetic, and recombinantly generated forms of MBP peptides and Class II polypeptides. These peptides and proteins can be recombinantly expressed in vitro or in vivo.
  • the peptides, polypeptides and complexes of the invention can be made and isolated using any method known in the art, and the invention provides a few exemplary means for generating such proteins.
  • means to make Class ILpeptide complexes are taught in, e.g., U.S. Patent Nos. (USPN) 5,194,425, issued March 16, 1993; 5,130,297, issued July 14, 1992;
  • MBP peptides and Class ILpeptide complexes of the invention can be synthesized, whole or in part, using chemical methods well known in the art (see e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res.
  • peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431 A Peptide
  • the newly synthesized peptide can be isolated and substantially purified by preparative high performance liquid chromatography (HPLC), see e.g., Creighton, Proteins,
  • composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing
  • Laser desorption mass spectrometry can also be used to evaluate the progress of peptide synthesis at all the necessary levels, including automated assembly, cleavage and deprotection chemistries, RP-HPLC analyses and purifications, and structural validation of the final product (Moore (1997) Methods Enzymol. 289:520-542).
  • Electrospray ionization mass spectrometry is an easy, rapid method for the verification of proper peptide synthesis and for the identification of most synthetic by-products (Burdick (1997) Methods Enzymol. 289:499-519).
  • amino acid sequences of the peptides and polypeptides of the invention can be alterred during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.
  • Modified peptides and proteins of the invention can be produced by, in addition to manipulation of nucleic acid coding sequence, e.g., with site-directed mutagenesis, chemical modification of polypeptide to introduce unnatural amino acid side chains (see e.g., Paetzel (1997) J. Biol. Chem. 272:9994-10003, for general methodology).
  • site-specific incorporation of biotin-containing amino acid biocytin see Gallivan (1997) Chem. Biol.
  • Class II polypeptides suitable for use in the present invention can also be isolated from a natural sources, such as a cell line expressing the appropriate DR allele or a patient of the appropriate genotype, using a variety of techniques well known in the art.
  • the cells can be solubilized by treatment with papain, by treatment with 3M KC1, or by treatment with detergent.
  • Detergent extraction of Class II protein from lymphocytes followed by affinity purification can also be used. Detergent can then be removed by dialysis or selective binding beads, e.g., Bio Beads.
  • the molecules can be obtained by isolation from any cell expressing the Class II molecule of interest, such as, e.g., B or T lymphocytes from an individual with the appropriate genotype, as one suffering from demyelinating autoimmune disease.
  • Suitable MHC molecules can be isolated from B or T cells which have been immortalized by transformation, e.g., as by B cell transformation with a replication deficient Epstein-Barr virus, utilizing techniques known in the art. Isolation of individual subunits from the isolated Class II molecule is easily achieved using standard techniques known to those skilled in the art. For example, alpha and beta subunits from Class II molecules can be separated using SDS/PAGE and electroelution. (see e.g., Rothenhausler (1990) Proc. Natl.
  • an additional "effector” composition is linked to the complexes of the invention to inhibit or abrogate the autoimmune reaction.
  • the "effector" portion of the molecule can be, e.g., a toxin, a chemotherapeutic agent, an antibody to a cytotoxic T lymphocyte (CTL) surface molecule, a lipase, or a toxic radioisotope emitting, e.g., gamma radiation from radioisotopes such as yttrium-90, phosphorus-32, lead-212, iodine- 131, or palladium- 109.
  • CTL cytotoxic T lymphocyte
  • a number of protein toxins are well known in the art including, e.g., ricin, diphtheria, gelonin, Pseudomonas toxin, and abrin.
  • Chemotherapeutic agents include, e.g., doxorubicin, daunorubicin, methotrexate, cytotoxin, and anti-sense RNA.
  • Antibiotics can also be used.
  • the toxin or other effector component is entrapped in a delivery system such as a liposome or dextran carrier; in these cases, either the active component or the carrier may be bound to the Class ILpeptide complex.
  • compositions of the present invention it is frequently desirable to modify the peptides or complexes to alter their pharmacokinetics and biodistribution (discused further below).
  • methods suitable for increasing serum half-life of the complexes include treatment to remove carbohydrates which are involved in the elimination of the complexes from the bloodstream.
  • substantially all of the carbohydrate moieties are removed by the treatment.
  • substantially all of the carbohydrate moieties are removed if at least about 75%, preferably about 90%, and most preferably about
  • the Class II polypeptide:MBP peptide complex can be formed by any standard means known in the art.
  • the peptides of the invention can be associated noncovalently with antigen binding sites by, e.g., simply mixing the two components. They can also be covalently bound to the antigen binding pocket using standard procedures by, e.g., photoaffmity labelling (see, e.g., Hall (1985) Biochemistry 24:5702-5711 ; Leuscher (1990) J. Biol. Chem. 265:1 1177-1 1184; Wraith (1989) Cell 59:247-255).
  • linkage examples include, e.g., attachment via carbohydrate/lectin groups on the glycoproteins (Husain (1995) Biochem. Mol Biol. Int. 36:669-677), as the carbohydrate moieties of Class II alpha and/or beta chains. Dehydration reactions using carbodiimides can be used. Heterobifunctional linkers such as N-hydroxysuccinimide ester (NHS), N-succinimidyl 3-(2-pyridyldithio)- propionate (SPDP), substituted 2-iminothiolanes, glutaraldehyde and the like can also be used (see, e.g., Traut (1995) Biochem. CellBiol.
  • the Class II: peptide complex can be designed as one contiguous recombinant polypeptide. See also, PCT Publication Nos. WO 96/40944, December 19, 1996; WO 96/40194, December 19, 1996; and,
  • Effectors or other fusion protein components can also be attached to the complex using these methods.
  • the sequence of preparing the complex depends on the components in each instance.
  • the peptide portion and MHC subunit component are noncovalently associated by contacting the peptide with the MHC subunit component, e.g., by mixing.
  • the effector is then covalently linked.
  • the effector and MHC subunit may be first conjugated and this conjugate complexed with the MBP peptide component. If the effector is itself a protein, the entire complex may be made directly from the appropriate encoding DNA using recombinant methods.
  • the peptides and MBP:Class II complexes of the invention can be assayed using a variety of in vitro models well known in the art. As discussed above, to activate CD4+ T cells, TCR binding by Class ILpeptide is not sufficient. An additional, "co-stimulatory" signal is needed. Interaction of a Class ILpeptide complex of the invention with TCR lacks a co-stimulatory signal. Thus, a state of antigen-specific T cell non-responsiveness is induced (Boussiotis (1994) Curr. Opin. Immunol. 6:797-807; Park (1997) Eur. J. Immunol. 27:1082-1090).
  • This "tolerance” or “anergy” immunosuppression and re-challenge non- responsiveness can be caused by T cell clonal anergy, by a nonresponsiveness induced by immunosuppressive cytokines, or both (Schwartz (1989) Cell 57:1073-1081; Quill (1987) J. Immunol. 138:3704-3712).
  • the complex is incubated with autoreactive T cells and the cells are rechallenged with MBP.
  • Peripheral blood T cells from patients with a demyelinating disease, such as MS, or myelin- (MBP-) reactive T cell clones can be used. T cells can be isolated before the analysis.
  • the autoreactive T cells can be restimulated with antigen (MBP or myelin) in vitro (using syngeneic APCs) before administration of the putative toleragen. "Resting" T cells (cells not stimulated in vitro) can be used.
  • the T cells are treated with varying amounts of a complex of the invention for varying amounts of time.
  • the binding of the complexes to the MBP-reactive T cells results in inhibiting or abrogating the in vitro autoimmune reaction.
  • the degree of immunosuppression or re-challenge non-responsiveness i.e., tolerance, anergy
  • T cell activation can be measured by a variety of means well known in the art.
  • T cell proliferation can be assessed, e.g., as measured by 3 H-thymidine uptake or by uptake of 3-(4,5-dimethyl- thiazol-2-7')-2,5 diphenyltetrazolium bromide (MTT) (see, e.g., Liu (1997) J. Neurochem.
  • MTT 3-(4,5-dimethyl- thiazol-2-7')-2,5 diphenyltetrazolium bromide
  • cytokines and lymphokines can be quantitated, e.g., interleukins, interferons (INFs) (e.g., gamma INF), tumor necrosis factors (TNFs) (e.g., TNF beta) and the like.
  • INFs interferons
  • TNFs tumor necrosis factors
  • Cell death can also be monitered, as it has been observed that prolonged incubation of resting T cells with soluble MHC-Class II peptide complexes results in T cell apoptosis (Arimilli (1996) Immunol, and Cell Biol. 74:96-104).
  • Cell death can be measured by a variety of known procedures, e.g., dye exclusion permeability.
  • Apoptosis can be assessed using, e.g., cellular DNA fragmentation, observation (as with transmission electron microscopy), detection and quantitation of apoptosis-associating protein, as bcl-2, and the like (see, e.g., Arimilli (1996) supra).
  • a preferred method of assessing the immunosuppressive efficacy of the Class ILpeptide complexes of the invention is through the use of a microphysiometer to measure the rate of production of acidic metabolites in T cells.
  • a microphysiometer measures the acidity of the principal catabolic products in mammalian cells, lactate and carbon dioxide.
  • Very small changes in the acidity of the cultural medium bathing a small sample of cells can be readily determined with a light- addressable potentiometric sensor.
  • the rate of acidification is used as a measure of catabolic rate of the cells being assayed. See, e.g., Parce (1989) Science 246:243-247; Owicki (1990) Proc. Natl Acad. Sci. USA 87:4007-4011; Renschler (1995) Cancer Res. 55:5642-5647; Beeson (1996) J. Exp. Med. 184:777-782.
  • MBP peptide or myelin polypeptide additive to a mixture of autoreactive T cells and syngeneic APCs results in an increase in acid release due to the antigen specific binding of autoreactive TCR and APC-bound Class ILMBP peptide complexes.
  • the immunosuppressive capability of an MBP peptide or Class ILMBP peptide complex of the invention can thus be evaluated by first adding a complex to an autoreactive T cell/ APC culture followed by antigen (MBP or myelin) challenge. Lack of or a relative decrease in cell activation indicative of immunosuppression can be measured by a lessening or lack of extracellular acidification.
  • a complex of the invention with an effector component is used.
  • the treatment can be two-fold: the individual is first treated with the Class ILMBP peptide complex to down-regulate the immune system; further down-regulation is achieved by treatment with complex and an effector component.
  • the invention also provides methods and reagents for isolating, detecting or quantitating the MBP peptides and Class II polypeptide complexes of the invention by a variety of methods.
  • the invention provides antibodies specifically immunoreactive under immunologically reactive conditions to an MBP peptide of the invention. These Abs can be used in the isolation, detection or quantitation of the MBP peptides or complexes of the invention.
  • Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art and described in the scientific and patent literature, see, e.g., Coligan, CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY (1991); Stites (eds.) BASIC AND CLINICAL IMMUNOLOGY (7th ed.) Lange Medical Publications, Los Altos, CA ("Stites”); Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY (1986); Kohler (1975) Nature 256:495; Harlow (1988)
  • ANTIBODIES A LABORATORY MANUAL, Cold Spring Harbor Publications, New York.
  • Such techniques include selection of antibodies from libraries of recombinant antibodies displayed in phage ("phage display libraries") or similar on cells. See, Huse (1989) Science 246:1275; Ward (1989) Nature 341 :544; Hoogenboom (1997) Trends Biotechnol 15:62-70; Katz (1997) Annu. Rev. Biophys. Biomol. Struct. 26:27-45.
  • Recombinant antibodies can be expressed by transient or stable expression vectors in mammalian cells, as in Norderhaug (1997) J. Immunol Methods 204:77-87; Boder (1997) "Yeast surface display for screening combinatorial polypeptide libraries," Nat. Biotechnol. 15:553-557. Purification of MBP Peptides and Complexes
  • the methods and reagents of the invention enable one to purify the MBP peptides and complexes of the invention from a variety of sources, depending on which natural source, synthetic or recombinant expression system selected, such as plant cells, larval homogenates, bacterial cells, yeast, mammalian cells, human cells, tissue culture media, transgenic plants and animals, to substantial purity.
  • natural source, synthetic or recombinant expression system selected such as plant cells, larval homogenates, bacterial cells, yeast, mammalian cells, human cells, tissue culture media, transgenic plants and animals, to substantial purity.
  • General information relating to standard purification procedures is well known in the patent and scientifice literature, as described supra; see also, e.g., Scopes, R. K., Protein Purification: Principles and Practice, 2nd ed.,
  • MBP peptides and complex polypeptides can also be expressed as proteins with one or more additional polypeptide domains linked thereto to facilitate cell killing (using, e.g. , effector agents, as described above), protein detection, purification, or other applications.
  • Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).
  • metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals
  • protein A domains that allow purification on immobilized immunoglobulin
  • the domain utilized in the FLAGS extension/affinity purification system Immunex Corp, Seattle WA.
  • the inclusion of a cleavable linker sequences such as Factor Xa or enterokinase
  • one expression vector includes a polypeptide-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (e.g., see Williams (1995) Biochemistry 34: 1787-1797).
  • the histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein.
  • Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell Biol, 12:441-53.
  • the MBP peptides and Class ILpeptide complexes of the invention are typically combined with a pharmaceutically acceptable carrier (excipient) to form a pharmacological composition.
  • Pharmaceutically acceptable carriers can contain a physiologically acceptable compound that acts to, e.g., stabilize, or increase or decrease the absorption or clearance rates of the pharmaceutical compositions of the invention.
  • Physiologically acceptable compounds can include, e.g., carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the peptides or polypeptide complexes, or excipients or other stabilizers and/or buffers.
  • Detergents can also used to stabilize or to increase or decrease the absorption of the pharmaceutical composition, see infra for exemplary detergents, including liposomal carriers.
  • physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives which are particularly useful for preventing the growth or action of microorganisms.
  • Various preservatives are well known and include, e.g., phenol and ascorbic acid.
  • a pharmaceutically acceptable carrier including a physiologically acceptable compound depends, for example, on the route of administration of the protein or polypeptide of the invention and on its particular physio-chemical characteristics.
  • compositions for administration will commonly comprise a solution of the peptide or polypeptide of the invention dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier if the composition is water-soluble.
  • aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like.
  • the formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
  • Additives can also include additional active ingredients such as bactericidal agents, or stabilizers.
  • the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate.
  • These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered.
  • the resulting aqueous solutions can be packaged for use as is, or lyophilized, the Iyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • concentration of MBP peptide and/or Class ILpeptide complex in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
  • Solid formulations can be used for enteral (oral) administration. They can be formulated as, e.g., pills, tablets, powders or capsules.
  • conventional nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10% to 95% of active ingredient (MBP peptide or complex).
  • a non-solid formulation can also be used for enteral administration.
  • the carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • Suitable pharmaceutical excipients include e.g., starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. It is recognized that the MBP peptides and polypeptide complexes of the invention, when administered orally, must be protected from digestion.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated can be used in the formulation.
  • penetrants are generally known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents can be used to facilitate permeation.
  • Transmucosal administration can be through nasal sprays or using suppositories. See, e.g., Banga, Chapt. 10; Sayani (1996) "Systemic delivery of peptides and proteins across absorptive mucosae” Crit. Rev. Ther. Drug Carrier Syst.
  • Transdermal delivery systems can also include, e.g., patches. See, e.g., Banga, Chapt. 9.
  • the peptides and polypeptide complexes can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally.
  • sustained delivery or sustained release mechanisms which can deliver the formulation internally.
  • biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a composition e.g., an MBP peptide:Class II polypeptide complex
  • a composition e.g., an MBP peptide:Class II polypeptide complex
  • the peptide or polypeptide can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, e.g., Patron (1998) Biotechniques 16:141-143; product and inhallation delivery systems for polypeptide macromolecules by, e.g., Dura Pharmaceuticals (San Diego, CA) , Aradigm (Hayward, CA), Aerogen (Santa Clara, CA), Inhale Therapeutic Systems (San Carlos, CA), and the like.
  • the pharmaceutical formulation can be administered in the form of an aerosol or mist.
  • the formulation can be supplied in finely divided form along with a surfactant and propellant.
  • the surfactant preferably is soluble in the propellant.
  • Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters.
  • the surfactant can constitute 0.1% to 20% by weight of the composition, preferably 0.25% to 5%.
  • the balance of the formulation is ordinarily propellant.
  • Liquefied propellants are typically gases at ambient conditions, and are condensed under pressure.
  • suitable liquefied propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably fluorinated or fluorochlorinated alkanes. Mixtures of the above can also be employed.
  • a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided compounds and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve. See, e.g., Edwards (1997) "Large porous particles for pulmonary drug delivery" Science 276: 1868-1871.
  • the device for delivering the formulation to respiratory tissue is an inhaler in which the formulation vaporizes.
  • Other liquid delivery systems include, e.g., air jet nebulizers.
  • a variety of formulation modifications can be used and manipulated to alter pharmacokinetics and biodistribution.
  • a number of methods for altering pharmacokinetics and biodistribution are known to one of ordinary skill in the art. Examples of such methods include protection of the complexes in vesicles composed of substances such as proteins, lipids (for example, liposomes, see below), carbohydrates, or synthetic polymers (discussed above).
  • lipids for example, liposomes, see below
  • carbohydrates for example, liposomes, see below
  • synthetic polymers discussed above.
  • the peptide and polypeptide complexes used in the methods of the invention can be delivered alone or as pharmaceutical compositions by any means known in the art, e.g., systemically, regionally, or locally; by intraarterial, intrathecal (IT), intravenous (IV), parenteral, intra-pleural cavity, topical, oral, or local administration, as subcutaneous, intra- tracheal (e.g., by aerosol) or transmucosal (e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa).
  • IT intraarterial, intrathecal
  • IV intravenous
  • parenteral intra-pleural cavity
  • topical oral
  • oral or local administration
  • subcutaneous, intra- tracheal e.g., by aerosol
  • transmucosal e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa
  • Actual methods for preparing administrable compositions will be known or apparent to those
  • Particularly preferred modes of administration include intraarterial or intrathecal (IT) injections, especially when it is desired to have a "regional effect," e.g., to focus on a specific organ, e.g., brain and CNS (see e.g., Gurun (1997) Anesth Analg. 85:317-323).
  • I intraarterial or intrathecal
  • intra-carotid artery injection if preferred where it is desired to deliver a peptide or polypeptide complex of the invention directly to the brain.
  • Parenteral administration is a preferred route of delivery if a high systemic dosage is needed.
  • Enteral administration is a preferred method if administration of peptide to induce oral tolerance is the therapeutic objective, see, e.g., Kennedy (1997) J. Immunol.
  • the pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. Dosages for typical peptide and polypeptide pharmaceutical compositions are well known to those of skill in the art. Such dosages are typically advisorial in nature and are adjusted depending on the particular therapeutic context, patient tolerance, etc. The amount of MBP peptide or Class ILpeptide complex adequate to accomplish this is defined as a "therapeutically effective dose.”
  • the dosage schedule and amounts effective for this use, i.e., the "dosing regimen” will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age, pharmaceutical formulation and concentration of active agent, and the like.
  • the mode of administration also is taken into consideration.
  • the dosage regimen must also take into consideration the pharmacokinetics, i.e., the pharmaceutical composition ' s rate of absorption, bioavailability, metabolism, clearance, and the like. See, e.g., the latest Remington's; Egleton (1997) "Bioavailability and transport of peptides and peptide drugs into the brain” Peptides 18:1431-1439; Langer (1990) Science 249:1527-1533.
  • compositions are administered to a patient suffering from a demyelinating disease in an amount sufficient to cure or at least partially arrest the disease and/or its complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the disease, general state of the patient's health, frequency and routes of administration, clinician's judgement, and the like.
  • a soluble Class ILpeptide complex pharmaceutical composition dosage for intravenous (IV) administration would be about 0.01 mg/hr to about 1.0 mg/hr administered over several hours (typically 1, 3, or 6 hours), which can be repeated for weeks with intermittant cycles.
  • CSF cerebrospinal fluid
  • Dosages can be determined empirically, by assessing the abatement or amelioration of symptions, or by objective criteria, such analysis of blood or histopathology specimens.
  • MS the disease is characterized by various complaints and findings of CNS dysfunction, with remissions and persistently recurring exacerbations. Onset usually is insidious. The most frequent presenting symptoms paresthesias in one or more extremities, in the trunk, or on one side of the face; weakness or clumsiness of a leg or a hand; or visual disturbances (e.g., partial blindness and pain in one eye, diplopia, dimness of vision, scotomas).
  • Tracts in the midbrain, pons, and cerebellum also are affected, and gray matter in both cerebrum and cord may be affected.
  • Cell bodies and axons usually are preserved, especially in early lesions. Later, axons may be destroyed, especially in the long tracts, and a fibrous gliosis gives the tracts their "sclerotic" appearance. Both early and late lesions may be found simultaneously.
  • the compositions of the invention are administered to arrest the progress of the disease and to reduce the onset, frequency or severity of these or other symptoms.
  • the dosage is between about 0.5 mg/kg and about 25 mg kg, with a preferred embodiment of about 3 mg/kg to about 15 mg/kg.
  • a unit dosage is between about 0.01 to 1000 mg per dose, with a preferred embodiment of about 10 to about 100 mg per dose. See also USPN 5,468,481, issued November 21, 1995.
  • peptide is adminstered enterally to induce oral tolerance in a dosage ranging from 10 to 2500 ug per day, with a preferred embodiment ofabout 20 to 50 ug per day. See, e.g., Barnett ( 1998) Arthritis Rheum. 41 :290-297, where oral administration of cartilage-derived type II collagen (to ameliorate arthritis) at a dosage ranges of 20, 100, 500, or 2,500 ug/day showed best results using 20 ug per day.
  • compositions containing the peptide and complexes of the invention can be administered alone or in conjunction with other therapeutic treatments. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. Liposom ⁇ l Formulations
  • the invention provides pharmaceuticals in which the transmembrane region of the Class II subunit of the complex is included.
  • the pharmaceutical formulations comprising this Class ILMBP peptide complex are incorporated in lipid monolayers or bilayers.
  • the invention also provides formulations in which water soluble peptides or complexes have been attached to the surface of the monolayer or bilayer.
  • peptides can be attached to hydrazide- PEG- (distearoylphosphatidyl) ethanolamine- containing liposomes (see, e.g., Zalipsky (1995) Bioconjug. Chem. 6:705-708).
  • Liposomes or any form of lipid membrane such as planar lipid membranes or the cell membrane of an intact cell, e.g., a red blood cell, can be used.
  • Liposomal formulations can be by any means, including administration intravenously, transdermally (see, e.g., Vutla (1996) J. Pharm. Sci. 85:5-8), transmucosally, or orally.
  • the invention also provides pharmaceutical preparations in which the peptides and/or complexes of the invention are incorporated within micelles and/or liposomes (see, e.g., Suntres (1994) J. Pharm. Pharmacol. 46:23-28; Woodle (1992) Pharm. Res. 9:260-265).
  • Liposomes and liposomal formulations can be prepared according to standard methods and are also well known in the art, see, e.g., Remington's; Akimaru (1995) Cytokines
  • liposomes of the present invention typically contain the Class ILpeptide complexes positioned on the surface of the liposome in such a manner that the complexes are available for interaction with the TCR.
  • the transmembrane region is usually first incorporated into the membrane at the time of forming the membrane.
  • the liposomes can also be used to target desired drugs (e.g. toxins or chemotherapeutic agents) to particular autoreactive T cells.
  • Liposome charge is an important determinant in liposome clearance from the blood, with negatively charged liposomes being taken up more rapidly by the reticuloendothelial system (Juliano (1975) Biochem. Biophys. Res. Commun. 63:651) and thus having shorter half-lives in the bloodstream. Incorporating phosphatidylethanolamine derivatives enhance the circulation time by preventing liposomal aggregation.
  • N-(omega-carboxy)acylamido-phosphatidylethanolamines into large unilamellar vesicles of L-alpha-distearoylphosphatidylcholine dramatically increases the in vivo liposomal circulation lifetime (see, e.g., Ahl (1997) Biochim. Biophys. Acta
  • Liposomes with prolonged circulation half-lives are typically desirable for therapeutic and diagnostic uses. For instance, liposomes which can be maintained from 8, 12, or up to 24 hours in the bloodstream are particularly preferred embodiments of the invention.
  • the liposomes are prepared with about 5 to 15 mole percent negatively charged phospholipids, such as phosphatidylglycerol, phosphatidylserine or phosphatidyl-inositol.
  • negatively charged phospholipids such as phosphatidylglycerol, also serve to prevent spontaneous liposome aggregating, and thus minimize the risk of undersized liposomal aggregate formation.
  • Membrane-rigidifying agents such as sphingomyelin or a saturated neutral phospholipid, at a concentration of at least about 50 mole percent, and 5 to 15 mole percent of monosialylganglioside, may provide increased circulation of the liposome preparation in the bloodstream, as generally described in USPN 4, 837,028.
  • the liposome suspension can include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alpha-tocopherol and water-soluble iron-specific chelators, such as ferrioxianine, are preferred.
  • the formulations of the invention can include multilamellar vesicles of heterogeneous sizes.
  • the vesicle-forming lipids are dissolved in a suitable organic solvent or solvent system and dried under vacuum or an inert gas to form a thin lipid film.
  • the film may be redissolved in a suitable solvent, such as tertiary butanol, and then lyophilized to form a more homogeneous lipid mixture which is in a more easily hydrated powderlike form.
  • This film is covered with an aqueous solution of the peptide or polypeptide complex and allowed to hydrate, typically over a 15 to 60 minute period with agitation.
  • the size distribution of the resulting multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions or by adding solubilizing detergents such as deoxycholate.
  • the hydration medium contains the peptide or complex at a concentration which is desired in the interior volume of the liposomes in the final liposome suspension.
  • the drug solution contains between 10 to 100 mg/ml of the peptides or complexes of the invention in a buffered saline solution.
  • the liposomes can be sized to achieve a desired size range and relatively narrow distribution of liposome sizes.
  • One preferred size range is about 0.2 to 0.4 microns, which allows the liposome suspension to be sterilized by filtration through a conventional filter, typically a 0.22 micron filter.
  • the filter sterilization method can be carried out on a high through-put basis if the liposomes have been sized down to about 0.2 to 0.4 microns.
  • Several techniques are available for sizing liposome to a desired size (see, e.g., U.S. Pat. No. 4,737,323).
  • Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles less than about 0.05 microns in size.
  • Homogenization is another method which relies on shearing energy to fragment large liposomes into smaller ones.
  • multilamellar vesicles are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, are observed.
  • the particle size distribution can be monitored by conventional laser-beam particle size discrimination.
  • Extrusion of liposome through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing liposome sizes to a relatively well-defined size distribution.
  • the suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved.
  • the liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.
  • the initial sized liposome suspension may contain up to 50% or more complex in a free (nonencapsulated) form.
  • Several methods are available for removing non-entrapped compound from a liposome suspension, if desired for a particular formulation.
  • the liposomes in the suspension are pelleted by high-speed centrifugation leaving free compound and very small liposomes in the supernatant.
  • Another method involves concentrating the suspension by ultrafiltration, then resuspending the concentrated liposomes in a replacement medium.
  • gel filtration can be used to separate large liposome particles from solute molecules.
  • the liposome suspension can be brought to a desired concentration for use in, e.g. , an intravenous, I.P, transdermal, or transmucosal administration.
  • liposomes comprising the peptides or Class ILpeptide complex can be administered parenterally or locally in a dose which varies according to, e.g., the manner of administration, the drug being delivered, the particular disease being treated, etc.
  • Micelles are commonly used in the art to increase solubility of molecules having nonpolar regions. One of skill will thus recognize that micelles are useful in compositions of the present invention.
  • Micelles comprising the complexes of the invention are prepared according to methods well known in the art (see, e.g., Remington's, Chap. 20).
  • Micelles comprising the peptides and/or complexes of the present invention are typically prepared using standard surfactants or detergents.
  • Micelles are formed by surfactants (molecules that contain a hydrophobic portion and one or more ionic or otherwise strongly hydrophilic groups) in aqueous solution.
  • Suitable surfactants include sodium laureate, sodium oleate, sodium lauryl sulfate, octaoxyethylene glycol monododecyl ether, octoxynol 9 and PLURONIC F-127 ® (Wyandotte
  • Preferred surfactants are nonionic polyoxyethylene and polyoxypropylene detergents compatible with IV injection such as PLURONIC F-127 ® , n-octyl-alpha-D- glucopyranoside, and the like.
  • Phospholipids such as those described for use in the production of liposomes, can also be used for micelle formation. Since, in some embodiments of the invention, the Class II subunit of the complexes comprise a lipophilic transmembrane region and a relatively hydrophilic extracellular domain, mixed micelles can be formed in the presence of common surfactants or phospholipids and the subunits.
  • the mixed micelles of the present invention can comprise any combination of the subunits, phospholipids and/or surfactants.
  • the micelles can comprise subunits and detergent, subunits in combination with both phospholipids and detergent, or subunits and phospholipid.
  • Kits can also be supplied for therapeutic or diagnostic uses.
  • the pharmaceutical formulation of the invention is in a lyophilized form, which can be placed in a container.
  • the complexes which can also be conjugated to a label or toxin, or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g. , serum albumin, or the like, and a set of instructions for use.
  • buffers such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g. , serum albumin, or the like, and a set of instructions for use.
  • these materials will be present in less than about 5% wt. based on the amount of complex and usually present in total amount of at least about 0.001% wt. based again on the protein concentration.
  • an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1% to 99% wt. of the total composition.
  • an antibody capable of binding to the complex is employed in an assay, this will usually be present in a separate vial.
  • the antibody is typically conjugated to a label and formulated according to techniques well known in the art.
  • antibody refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described supra.
  • conservative substitution refers to a change in the amino acid composition of a peptide or protein, such as polypeptide comprising the MBP peptide sequences of the invention, that does not substantially alter the peptide' s or protein's activity.
  • amino acid substitutions of those amino acids that are not critical for protein activity or substitution of amino acids with other amino acids having similar properties e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.
  • amino acids having similar properties e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.
  • a polypeptide sequence of the invention implicitly encompasses conservatively substituted variants thereof.
  • Conservative substitution tables providing functionally similar amino acids are well known in the art.
  • the following six groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (a), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W) (see also, Creighton (1984) Proteins, W.H. Freeman and Company).
  • substitutions are not the only possible conservative substitutions.
  • nucleic acid sequence of the invention implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated.
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer (1991) Nucleic Acid Res. 19:5081; Ohtsuka (1985) J Biol. Chem. 260:2605-2608; Rossolini (1994) Mo/. Cell Probes 8:91-98).
  • a “fusion protein” refers to a composition comprising at least one polypeptide or peptide domain which is associated with a second domain.
  • the second domain can be a polypeptide, peptide, polysaccharide, or the like.
  • the "fusion” can be an association generated by a chemical linking or by a charge (electrostatic attraction, i.e., salt bridges, H-bonding, etc.) interaction. If the polypeptides are recombinant, the "fusion protein” can be translated from a common message. Alternatively, the compositions of the domains can be linked by any chemical or electrostatic means.
  • heterologous sequence refers to any amino acid or nucleic acid sequence that is not a myelin basic protein sequence.
  • isolated when referring to a molecule or composition, such as, for example, an MBP peptide, Class ILpeptide complex, or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (e.g., RNAs), or other contaminants with which it is associated in vivo or in its naturally occurring state.
  • a polypeptide or nucleic acid is considered isolated when it has been isolated from any other component with which it is naturally associated, e.g., cell membrane, as in a cell extract.
  • An isolated composition can, however, also be substantially pure.
  • An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-PAGE) or high performance liquid chromatography (HPLC).
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form.
  • the term encompasses nucleic acids, i.e., oligonucleotides, containing known analogues of natural nucleotides which have similar or improved binding properties, for the purposes desired, as the reference nucleic acid.
  • the term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired.
  • nucleic-acid-like structures with synthetic backbones are examples of synthetic backbones.
  • DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see Oligonucleotides and Analogues, a Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) J. Med. Chem.
  • PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO 97/03211 ; WO 96/39154; Mata (1997) Toxicol Appl Pharmacol 144:189-197. Other synthetic backbones encompasses by the term include methylphosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) Biochemistry 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156).
  • nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product.
  • composition refers to a composition suitable for pharmaceutical use in a subject.
  • the pharmaceutical compositions of this invention are formulations that comprise a pharmacologically effective amount of an MBP peptide and/or a Class ILpeptide complex and a pharmaceutically acceptable carrier.
  • to treat and “treatment” refer to prophylactic and therapeutic treatment administered to a subject.
  • Prophylactic treatment includes administering treatment to an individual who does not have a disease or condition, or does not exhibit signs of a disease or condition, or exhibits only early signs of a disease or condition for the purpose of decreasing or abrogating the risk of acquiring the disease or condition or decreasing or abrogating a symptom or a pathologic condition arising from or related to the disease or pathology.
  • the invention provides a method to treat a T cell mediated immune response against myelin basic protein in a subject by administration of an MBP peptide and/or a Class ILpeptide complex to an individual who is considered a high risk for developing a demyelinating disease or condition.
  • Therapeutic treatment also includes administering treatment to an individual who exhibits signs of pathology or disease, or is considered at risk for developing or incurring such a condition or disease, for the purpose of preventing, diminishing, ameliorating or eliminating any symptoms or pathology.
  • the methods of the invention provide a means to treat demyelinating disease and to prevent, diminish, eliminate or otherwise ameliorate the disease's clinical symptoms and tissue pathology, as discussed above.
  • a "pharmacologically effective amount” is the amount of compound administered to the individual to prophylactically or therapeutically effectively treat an individual for a disease or condition.
  • Example 1 Identification of core structure and critical TCR contact residues in an antigenic MBP peptide by measuring T cell activation signals
  • the invention provides novel MBP peptides and MPB peptide:Class II complexes, pharmaceutical formulations comprising these compositions, and a method for treating a T cell mediated immune response against MPB in a subject by administration of these novel compositions.
  • novel MBP peptides which include the core TCR recognition sequence amino acid residues involved in the binding of autoreactive TCR associated with demyelinating disease, as MS, with MBP peptide and an appropriate Class II molecule.
  • a novel, minimal structure and critical residues for its interaction with autoreactive TCR was identified for human myelin basic protein (MBP) peptide.
  • Synthetic peptide analogs were incubated with TCRs on a DRB5*0101 -restricted transformed human T cell clone (SS8T) expressing MHC class II (DR2) molecules.
  • SS8T DRB5*0101 -restricted transformed human T cell clone
  • DR2 MHC class II
  • a silicon-based biosensor microphysiometer was used to measure the real time cell response to a T cell activation event stimulated by the binding of Class ILpeptide to TCR.
  • the microphysiometer monitored changes in extracellular acidification rate in response to MBP peptide:Class II polypeptide binding to autoreactive TCRs. Increases in the extracellular acidification rate is a direct result of early T cell signaling events, such as high affinity TCR binding to a Class ILpeptide complex.
  • HVS Herpes virus saimiri immortalized human T cells were used in in vitro assays to identify the novel MBP peptides of the invention.
  • HVS T cells express the same level of TCR as normal human T cells, without any loss of antigen recognition (Weber (1993) Proc. Natl. Acad. Sci. USA 90: 11049).
  • the HVS transformed human T cell clone used in these assays designated SS8T, was generated from an MS patient.
  • SS8T has previously been characterized as being restricted to the HLA Class II DR2(DRB5*0101) polypeptide and the MBP(84-102) peptide (Weber (1993) supra ).
  • a modified peptide analog of MBP(84- 102) with a N-acetylated tyrosine residue at the N-terminus has been characterized as being recognized by SS8T transformed T cells when complexed with HLA DR2 (DRB5*0101) (Mukku (1995) o . Immunol 32:555; Arimilli (1995) J. Biol. Chem. 270:971).
  • HLA DR2 DRB5*0101
  • alanine analog peptides For alanine analog peptides, a single amino acid was substituted with alanine for each residue in the MBP(90-102)Y 83 sequence.
  • the critical MBP peptide amino acid residues required for TCR engagement in this model system depend on two factors; the peptide residues responsible for binding to MHC class II binding groove amino acid residues (the peptide agretope) and the effective interaction of some of the amino acid residues of the peptide with TCR (the epitope).
  • the epitope To determine the minimum length of the immunodominant epitope, various terminally truncated peptides were incubated at different concentrations with SS8T cells in a microtiter plate for 48 hours at 37°C.
  • culture fluids were tested for the presence of secreted gamma IFN and TNF-beta by ELISA using monoclonal antibodies (mAbs) to each (anti-human gamma IFN mAb and rabbit anti-human gamma IFN polyclonal Ab, Endogen Inc., Woburn, MA; peroxidase-conjugated goat IgG and rabbit IgG, Jackson
  • Biosystems 431 A automated peptide synthesizer. The deprotected, crude peptides were purified by reverse-phase HPLC, and the homogeneity and identity of the purified peptides were confirmed by mass spectrometry. All terminally truncated and alanine analog MBP peptides (Fig. 1) were synthesized by solid phase peptide synthesis using Fmoc chemistry. All chemicals, including the Rink amide MBRA resin and side chain protected Fmoc amino acids were obtained from Nova Biochem, San Diego, CA.
  • HBTU/HOBt or PyBOP activation chemistry were employed for protected amino acid coupling on ABI 431 A automated peptide synthesizer or ABIMED/GILSON AMS 422 multiple peptide synthesizer, as described by Luu (1996) Int. J. Peptide Protein Res. 47:91. After peptides were synthesized on solid phase, they were cleaved by TFA containing 5% 4-methoxybenzenethiol and 5% 4-methylmercaptophenol as scavengers. The crude peptides were precipitated by pentane: acetone mixture (4:1, v:v) and isolated by centrifugation.
  • Peptides were washed with pentane: acetone mixture three times followed by pentane and were dried in vacuum. Peptides were purified by reverse phase HPLC using a C18 column; the pure fractions were pooled and lyophilized. Peptides were characterized by electron spray mass spectrometry. T cells were cultured in RPMI 1640 medium supplemented with 2 mM
  • TNF-beta For the detection of TNF-beta, Nunc Maxisorb 96-well plates were coated with anti-human TNF-beta mAb at a concentration of 0.5 ug/well and incubated at 4°C overnight. The wells were blocked with 0.1% bovine serum albumin, and samples were incubated at RT for 2 h. A standard curve was generated by using recombinant human TNF-beta with a dilution range of 500 to 0.01 ng/ml. Goat anti-human TNF-beta was then added at a concentration of 1 ug/ml and plates were incubated at 25°C for an additional 2 h.
  • Freshly cultured SS8T cells were immobilized into microphysiometer cell capsules as described by Nag et al., 1992, using low-melt agarose (Molecular Devices Corp., Sunnyvale, CA). Briefly, T cells were rested from IL-2 pulsing for 2 days. Cells were counted and suspended in a serum-free loading medium (low-buffering RPMI 1640 containing 10% fatty acid free, endotoxin-free, BSA). Cells were collected by centrifugation and resuspended at a concentration of 3 x 10 5 T cells per 7.5 ul of loading medium.
  • serum-free loading medium low-buffering RPMI 1640 containing 10% fatty acid free, endotoxin-free, BSA
  • Figure 2A, 2B and 2C show the results of these analyses, demonstrating increased levels of gamma-IFN, TNF-beta and extracellular acidification rates with first six N-terminal truncated peptides: MBP(84-102) (SEQ ID NO:2), MBP(85-102) (SEQ ID NO:3),
  • MBP(86-102) SEQ ID NO:4
  • MBP(87-102) SEQ ID NO:5
  • MBP(88-102) SEQ IDNO:6
  • MBP(89-102) SEQ ID NO:7.
  • the SS8T cells exposed to these peptides show a 2 to 4 fold increase in gamma IFN and a 3 to 4 fold increase in TNF-beta production in a dose dependent manner (Fig. 2A, 2B).
  • increase in acidification rates at 118% of basal rate were observed within 10 min (Fig. 2C), indicating that the amino acid residue 84, residue
  • residue 85, residue 86, residue 87, residue 88, and residue 89 are not important for TCR recognition in SS8T cells.
  • the gamma-IFN and TNF-beta cytokine concentrations measured after 48 hour (h) correlated well with the acidification rates.
  • Figure 2D, 2E and 2F show results comparing the gamma-IFN, TNF-beta and acidification rates of next five N-terminus truncated MBP(90-102) (SEQ ID NO:8),
  • Alanine substitution is more popular since it is the simplest side chain amino acid with a chiral center, and it creates only minor disturbances in the secondary structure of polypeptides and proteins. It is a common replacement for all but aromatic amino acids, based on comparison of evolutionary related proteins. Therefore, an alanine substitution strategy was used to define important TCR contact residues.
  • Various analog peptides from MBP(90-102) (SEQ ID NO: 8) with single amino acid substitutions using alanine were incubated with SS8T cells. The culture fluids were tested for gamma-IFN, TNF-beta and compared with acidification rates.
  • Figures 4A, 4B and 4C show that two peptides,
  • MBP(83-102)A90 SEQ ID NO:24
  • MBP(83-102)A92 SEQ ID NO:26
  • MBP(83-102)A91 SEQ ID NO:25
  • MDP(83-102)A93 SEQ ID NO:27
  • MDP(83-102)A94 SEQ ID NO:28
  • MDP(83-102)A95 SEQ ID NO:29
  • MBP(124-143) (SEQ ID NO:37) was used as a negative control.
  • MBP(124-143) peptide has a high affinity for binding to DR2 (Mukku (1995) supra), but does not stimulate DRB5*0101 restricted T cells (Arimilli (1995) supra).
  • Figure 5A highlights (boxed area) the core TCR recognition sequence as
  • MBP(91-100) (SEQ ID NO:38).
  • this peptide was identified by measuring extracellular acidification rates and by the gamma-IFN, TNF-beta cytokine response in SS8T cells using terminally truncated peptides.
  • Figure 5B indicates (by arrows) the important amino acid residues involved in TCR contact as F-91, K-93, N-94, 1-95, and V-96. As described above, these amino acids were identified from extracellular acidification rates and gamma-
  • IFN IFN, TNF-beta cytokine response in SS8T cells by using alanine analog peptides.
  • T cell stimulation is the direct consequence of TCR engagement through MHC-peptide complex formed on the cell surface or due to the direct binding of the peptide to the TCR.
  • Ab blocking experiments were performed using anti-TCR mAb and anti-Class II mAb (hybridoma cell line L243, producing mAb to monomorphic human HLA DR molecules was obtained from American Type Culture Collection, Bethesda, MD).
  • Transformed SS8T human T cells bear Class II on their surface, confirmed by flow cytometry. SS8T cells were incubated with either anti-TCR or anti-DR Ab to block the TCR and Class II sites.
  • Later cell activation events are measured within 48 hours; representative later activation events measured in these studies were the gamma-IFN and TNF-beta cytokine response. Measurement of early and late activation events are equivalent in identifying peptides that are important for TCR recognition, as was done to identify the novel MBP peptides of the invention.
  • These complexes comprise an MHC Class II complex capable of binding a T cell receptor, the complex consisting essentially of: an MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket and a myelin basic protein having an amino acid sequence Phe -X - Lys - R, - He - Val - X - X - X - Thr - X -X , wherein X is any amino acid, and R, is Asn or Gin; wherein the MBP peptide is bound to the MHC Class II component antigen binding pocket.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention a trait de manière générale au traitement de maladies auto-immunes du système nerveux central caractérisées par une démyélinisation. En particulier, l'invention a trait à de nouveaux peptides dérivés de la protéine basique de myéline (MBP) humaine. Lorsqu'ils forment des complexes avec une molécule appropriée du complexe majeur d'histocompatibilité (CMH), ces peptides peuvent être utilisés pour traiter la sclérose en plaques et d'autres maladies auto-immunes démyélinisantes.
PCT/US1999/009930 1998-05-05 1999-05-05 Peptides de proteine basique de myeline et utilisations de ceux-ci Ceased WO1999057241A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ507901A NZ507901A (en) 1998-05-05 1999-05-05 Isolated myelin basic protein (MBP) for treating mutliple sclerosis
HK02101092.3A HK1039636A1 (zh) 1998-05-05 1999-05-05 髓磷脂碱性蛋白肽及其应用
AU37890/99A AU3789099A (en) 1998-05-05 1999-05-05 Myelin basic protein peptides and uses thereof
CA002330826A CA2330826A1 (fr) 1998-05-05 1999-05-05 Peptides de proteine basique de myeline et utilisations de ceux-ci
JP2000547197A JP2002513558A (ja) 1998-05-05 1999-05-05 ミエリン塩基性タンパク質ペプチドおよびその使用
EP99920379A EP1080185A4 (fr) 1998-05-05 1999-05-05 Peptides de proteine basique de myeline et utilisations de ceux-ci
NO20005547A NO20005547L (no) 1998-05-05 2000-11-03 Myelinbasisproteinpeptider og anvendelser derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7310998A 1998-05-05 1998-05-05
US09/073,109 1998-05-05

Publications (3)

Publication Number Publication Date
WO1999057241A2 true WO1999057241A2 (fr) 1999-11-11
WO1999057241A3 WO1999057241A3 (fr) 2000-01-13
WO1999057241A9 WO1999057241A9 (fr) 2000-02-17

Family

ID=22111789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009930 Ceased WO1999057241A2 (fr) 1998-05-05 1999-05-05 Peptides de proteine basique de myeline et utilisations de ceux-ci

Country Status (10)

Country Link
EP (1) EP1080185A4 (fr)
JP (1) JP2002513558A (fr)
CN (1) CN1308671A (fr)
AU (1) AU3789099A (fr)
CA (1) CA2330826A1 (fr)
HK (1) HK1039636A1 (fr)
NO (1) NO20005547L (fr)
NZ (1) NZ507901A (fr)
WO (1) WO1999057241A2 (fr)
ZA (1) ZA200006268B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000733A3 (fr) * 2001-06-22 2003-11-13 Univ Firenze Glycopeptides, preparation et utilisation de ces glycopeptides pour le diagnostic ou le traitement de la sclerose en plaques
EP1487480A4 (fr) * 2001-05-01 2005-09-21 Univ California Molecules hybrides et methodes de traitement des maladies immunitaires
US7534440B2 (en) 2001-05-01 2009-05-19 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
WO2009066175A1 (fr) * 2007-11-20 2009-05-28 Eldrug S.A. Analogues peptidiques et leurs conjugués
CN107735408A (zh) * 2015-03-30 2018-02-23 国立大学法人大阪大学 免疫用肽、免疫用肽的制备方法、包含其的免疫疾病用医药组合物及免疫疾病的治疗方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4461303A3 (fr) * 2019-06-18 2025-05-14 The Scripps Research Institute Procédés et compositions pour le traitement d'états inflammatoires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
SK51297A3 (en) * 1994-10-25 1998-03-04 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
EP0833930A2 (fr) * 1995-06-07 1998-04-08 ZymoGenetics, Inc. Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487480A4 (fr) * 2001-05-01 2005-09-21 Univ California Molecules hybrides et methodes de traitement des maladies immunitaires
US7534440B2 (en) 2001-05-01 2009-05-19 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7879324B2 (en) 2001-05-01 2011-02-01 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7879334B1 (en) 2001-05-01 2011-02-01 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003000733A3 (fr) * 2001-06-22 2003-11-13 Univ Firenze Glycopeptides, preparation et utilisation de ces glycopeptides pour le diagnostic ou le traitement de la sclerose en plaques
US7037893B2 (en) 2001-06-22 2006-05-02 Universita' Degli Studi Di Firenze Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2009066175A1 (fr) * 2007-11-20 2009-05-28 Eldrug S.A. Analogues peptidiques et leurs conjugués
CN101990545A (zh) * 2007-11-20 2011-03-23 埃尔德鲁格股份有限公司 肽类似物及其结合物
CN107735408A (zh) * 2015-03-30 2018-02-23 国立大学法人大阪大学 免疫用肽、免疫用肽的制备方法、包含其的免疫疾病用医药组合物及免疫疾病的治疗方法
EP3279218A4 (fr) * 2015-03-30 2018-12-05 Osaka University Peptide immunisant, procédé de fabrication du peptide immunisant, composition pharmaceutique contenant celui-ci et ciblant les troubles de l'immunité, et méthode de traitement de troubles de l'immunité

Also Published As

Publication number Publication date
WO1999057241A9 (fr) 2000-02-17
AU3789099A (en) 1999-11-23
WO1999057241A3 (fr) 2000-01-13
JP2002513558A (ja) 2002-05-14
EP1080185A4 (fr) 2005-01-26
HK1039636A1 (zh) 2002-05-03
ZA200006268B (en) 2001-08-22
NO20005547L (no) 2001-01-02
NZ507901A (en) 2003-06-30
CN1308671A (zh) 2001-08-15
NO20005547D0 (no) 2000-11-03
EP1080185A2 (fr) 2001-03-07
CA2330826A1 (fr) 1999-11-11

Similar Documents

Publication Publication Date Title
JP3487849B2 (ja) 自己免疫性を改善せしめるうえで有用なｍｈｃコンジュゲート
US7081345B1 (en) Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
JP2019116477A (ja) 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
JP2002517977A (ja) Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
JP2005508913A (ja) 樹状細胞の活性化のためのｈｍｇｂ１の使用
KR20010085861A (ko) Ｗｔ1 특이적 면역요법용 조성물 및 방법
JPH10327880A (ja) ヒト・ナトリウム依存性リン酸輸送体（ｉｐｔ−１）
AU3173199A (en) Novel peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
CA2168268C (fr) Prophylaxie du sida
SI9520118A (sl) Sestavki in zdravljenje multiple skleroze
CA2355334A1 (fr) Preparations pharmaceutiques et methodes visant a inhiber la croissance de tumeurs
JP2002531583A (ja) Ｍｕｃ−１アンタゴニストおよび免疫疾患の治療方法。
EP2692733B1 (fr) Acides nucléiques codant pour des formes solubles du CD83
WO1999057241A2 (fr) Peptides de proteine basique de myeline et utilisations de ceux-ci
US5922567A (en) Two new human DNAJ-like proteins
US20080199443A1 (en) Bone Morphogenetic Variants, Compositions and Methods of Treatment
WO2003004612A2 (fr) Inhibiteur de l'activation des leucocytes t
US20020127648A1 (en) Novel human C5a-like receptor
KR20020026530A (ko) Ｔ-세포 수용체 γ알터네이트 리딩 프레임단백질(ＴＡＲＰ) 및 그 용도
EP1373495B1 (fr) Proteine bisulfure isomerase et proteines homologues transporteuses d'abc impliquees dans la regulation de l'hemostase energetique
MXPA00010759A (en) Myelin basic protein peptides and uses thereof
US5965394A (en) Human importin alpha homolog
US6312895B1 (en) Human selenium-binding protein
US5989820A (en) Polynucleotides encoding a human adipophilin protein homolog
WO2005014612A1 (fr) Nouveau variant d'epissage de ctla-4

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808248.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2330826

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010759

Country of ref document: MX

Ref document number: 507901

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000/06268

Country of ref document: ZA

Ref document number: 200006268

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 547197

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 37890/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999920379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999920379

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999920379

Country of ref document: EP